Reply: Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. J Med Econ. 2020;23(6):641-649

J Med Econ. 2020 Dec;23(12):1501-1502. doi: 10.1080/13696998.2020.1835857. Epub 2020 Nov 6.

Authors

Jashin J Wu¹, Jes B Hansen², Dharm S Patel², Nanna Nyholm², Karen A Veverka², Andrine R Swensen²

Affiliations

¹ Dermatology Research and Education Foundation, Irvine, CA, USA.
² LEO Pharma, Ballerup, Denmark, and Madison, NJ, USA.

PMID: 33040632
DOI: 10.1080/13696998.2020.1835857

No abstract available

Publication types

Comment

MeSH terms

Betamethasone* / analogs & derivatives
Calcitriol / analogs & derivatives
Clobetasol / analogs & derivatives
Humans
Nicotinic Acids
Psoriasis* / drug therapy

Substances

Nicotinic Acids
calcipotriene
tazarotene
betamethasone-17,21-dipropionate
Betamethasone
halobetasol
Clobetasol
Calcitriol